Ann: Positive Results for Australian Prospective Paediatric Study, page-104

The outstanding results delivered by the Breathe Easy prospective study are consistent with our expectations, and for diseases such as pneumonia and asthma have even exceeded our expectations. This formal confirmation of ResApp’s algorithms’ robust performance will allow us to provide key diagnostic products in an array of clinical settings, especially in telehealth - one of the fastest growing segments in healthcare - where up to 50% of consultations are respiratory related”, said Tony Keating, CEO and Managing Director of ResApp. “We now have a solid dataset to underpin our forthcoming CE mark and TGA submissions which will propel the commercialisation of our products in Europe, Australia and the rest of the world outside the US. The successful completion of Breathe Easy also gives us additional data, experience and confidence as we finalise our US SMARTCOUGH-C-2 study.”

Are we reading the same thing???